Baseline tumor-infiltrating lymphocyte patterns and response to immune checkpoint inhibition in metastatic cutaneous melanoma
European Journal of Cancer · 2024-09 · 208 · 114190
DOI: 10.1016/j.ejca.2024.114190 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Cancer, 2024-09. Verfasst von Isabella A J van Duin und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, 3584 CG Utrecht, the Netherlands. Hauptthemen laut MEDLINE: Melanoma, Lymphocytes, Tumor-Infiltrating, Skin Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hanarth Fund Foundation, Philips, ZonMw.
Abstract (Originalsprache)
INTRODUCTION: The presence of tumor-infiltrating lymphocytes (TILs) in melanoma has been linked to survival. Their predictive capability for immune checkpoint inhibition (ICI) response remains uncertain. Therefore, we investigated the association between treatment response and TILs in the largest cohort to date and analyzed if this association was independent of known clinical predictors. METHODS: In this multicenter cohort study, patients who received first-line anti-PD1 ± anti-CTLA4 for advanced melanoma were identified. TILs were scored on hematoxylin and eosin (H&E) slides of primary melanoma and pre-treatment metastases using the validated TILs-WG, Clark and MIA score. The primary outcome was objective response rate (ORR), with progression free survival and overall survival being secondary outcomes. Univariable and multivariable logistic regression and Cox proportional hazard were performed, adjusting for known clinical predictors. RESULTS: Metastatic melanoma specimens were available for 650 patients and primary specimens for 565 patients. No association was found in primary melanoma specimens. In metastatic specimens, a 10-point increase in the TILs-WG score was associated with a higher probability of response (aOR 1.17, 95 % CI 1.07-1.28), increased PFS (HR 0.93, 95 % CI 0.87-0.996), and OS (HR 0.94, 95 % CI 0.89-0.99). When categorized, patients in the highest tertile TILs-WG score (15-100 %) compared to the lowest tertile (0 %) had a longer median PFS (13.1 vs. 7.3 months, p = 0.04) and OS (49.4 vs. 19.5 months, p = 0.003). Similar results were noted using the MIA and Clark scores. CONCLUSION: In advanced melanoma patients, TIL patterns on H&E slides of pre-treatment metastases, regardless of measurement method, are independently associated with ICI response. TILs are easily scored on readily available H&Es, facilitating the use of this biomarker in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, 3584 CG Utrecht, the Netherlands.
- Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, 3584 CG Utrecht, the Netherlands. Electronic address: m.schuiveling@umcutrecht.nl.
- Image Sciences Institute, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, 3584 CG Utrecht, the Netherlands.
- Department of Data Science and Biostatistics, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, 3584 CG Utrecht, the Netherlands.
- Department of Medical Oncology, Zuyderland Medical Center Sittard, Dr. H. van der Hoffplein 1, Sittard-Geleen 6162 BG, the Netherlands.
- Department of Medical Oncology, Radboud University Medical Center, Geert Grooteplein Zuid 10, Nijmegen 6525 GA, the Netherlands.
Förderung
- Hanarth Fund Foundation
- Philips
- ZonMw
Zitieren
APA
van Duin, I. A. J., Schuiveling, M., Ter Maat, L. S., van Amsterdam, W. A. C., van den Berkmortel, F., Boers-Sonderen, M., de Groot, J. W. B., Hospers, G. A. P., Kapiteijn, E., Labots, M., Piersma, D., Schrader, A. M. R., Vreugdenhil, G., Westgeest, H., Veta, M., Blokx, W. A. M., van Diest, P. J., & Suijkerbuijk, K. P. M. (2024). Baseline tumor-infiltrating lymphocyte patterns and response to immune checkpoint inhibition in metastatic cutaneous melanoma. European Journal of Cancer, 208, 114190. https://doi.org/10.1016/j.ejca.2024.114190
Vancouver
van Duin IAJ, Schuiveling M, Ter Maat LS, van Amsterdam WAC, van den Berkmortel F, Boers-Sonderen M, et al. Baseline tumor-infiltrating lymphocyte patterns and response to immune checkpoint inhibition in metastatic cutaneous melanoma. European Journal of Cancer. 2024;208:114190. doi:10.1016/j.ejca.2024.114190
BibTeX
@article{vanDuin2024,
author = {van Duin, Isabella A J and Schuiveling, Mark and Ter Maat, Laurens S and van Amsterdam, Wouter A C and van den Berkmortel, Franchette and Boers-Sonderen, Marye and de Groot, Jan Willem B and Hospers, Geke A P and Kapiteijn, Ellen and Labots, Mariette and Piersma, Djura and Schrader, Anne M R and Vreugdenhil, Gerard and Westgeest, Hans and Veta, Mitko and Blokx, Willeke A M and van Diest, Paul J and Suijkerbuijk, Karijn P M},
title = {Baseline tumor-infiltrating lymphocyte patterns and response to immune checkpoint inhibition in metastatic cutaneous melanoma},
journal = {European Journal of Cancer},
year = {2024},
volume = {208},
pages = {114190},
doi = {10.1016/j.ejca.2024.114190}
}
EUVIMED